24th Symposium on Medicinal Chemistry in Eastern England

Thursday, 25th April 2013
Fielder Centre, Hatfield, Hertfordshire, UK

09:30  Registration and refreshments
Chairman: Prof Simon Ward (University of Sussex)

10:00  Welcome and introduction

10:05  Epigenetic modulation of the pro-inflammatory macrophage response -
discovery of a selective Jumonji H3K27 demethylase inhibitor
Robert Sheppard (GlaxoSmithKline)

10:45  Discovery of potent and selective Syk inhibitors for the treatment of asthma
Bernat Vidal (Almirall)

11:25  Development of acidic molecules as drug candidates: A medicinal chemistry
perspective
Nigel Swain (Pfizer)

12:05  Lunch
Chairman: Prof Robin Ganellin (University College London)

13:10  GNE-7915: A potent, selective and brain-penetrant LRRK2 inhibitor
Mark Chambers (BioFocus)

13:50  Discovery of a novel chemotype of ENaC blockers for the treatment of cystic
fibrosis
Tom Hunt (Novartis)

14:30  From virtual to clinical: The discovery of the EP4 receptor antagonist, AP-1531
David Clark (Argenta)

15:10  Refreshments

15:30  Structure-based design of irreversible kinase inhibitors
Richard Ward (AstraZeneca)

16:10  From PSK1404 to GLPG0187, clinical candidate: How to overcome toxicity in
the integrin receptor antagonist program
Bertrand Heckmann (Galapagos)

16:50  Concluding remarks

17:00  Close